Methods and compounds for treating disorders

A compound having the structure of Formula K-1, Formula K-2, Formula M-2, Formula M-3, or Formula O-1:

• wherein
• Y2 is N or CR23;
• R22 is H, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
• R23 is H, halogen, optionally substituted C1-C6 alkyl, or optionally substituted C6-C10 aryl;
• s is 0, 1, 2, 3, or 4;
• each R25 is, independently, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, hydroxyl, thiol, or optionally substituted amino;
• R53 is H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
• R54 is H or optionally substituted C2-C9 heteroaryl;
• R55 is H or NRa, wherein Ra is H, optionally substituted C1-C6alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
• X5 is N or CR56a;
• X6 is N or CR56b;
• each of X7 and X8 is, independently, N or CH;
• each of R56a and R56b is, independently, H or NRa, wherein each Ra is H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
• R57 is optionally substituted C2-C10 heterocyclyl;
• Y2 is N or CR58a;
• Y3 is N or CR58b;
• and
• each of R58a and R58b is, independently, H or optionally substituted C1-C6 alkyl,
• wherein if R53 is H and R54 is H, then R55 is NRa;
• if R54 is H and R55 is H, then R53 is optionally substituted C3-C10 carbocyclyl;
• and if R53 is H and R55 is H, then R54 is optionally substituted C2-C9 heteroaryl,
• or a pharmaceutically acceptable salt thereof.

A compound having the structure of Formula I:

• A-L-B Formula I,
• wherein
• L is a linker;
• B is a degradation moiety;
• and
• A has the structure of Formula E-3, Formula E-4, Formula G-2, Formula G-3, or Formula E-5:
• wherein
• Y2 is N or CR23;
• R22 is H, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
• R23 is H, halogen, optionally substituted C1-C6 alkyl, or optionally substituted C6-C10 aryl;
• s is 0, 1, 2, 3, or 4;
• each R25 is, independently, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, hydroxyl, thiol, or optionally substituted amino;
• R53 is H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
• R54 is H or optionally substituted C2-C9 heteroaryl;
• R55 is H or NRa, wherein Ra is H, optionally substituted C1-C6alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
• each of X5 and X6 is, independently, N or CR56;
• each of X7 and X8 is, independently, N or CH;
• each R56 is, independently, H or NRa, wherein Ra is H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
• R57 is optionally substituted C2-C10 heterocyclyl;
• each of Y2 and Y3 is, independently, N or CR58;
• and
• each R58 is, independently, H or optionally substituted C1-C6 alkyl,
• wherein if R53 is H and R54 is H, then R55 is NRa;
• if R54 is H and R55 is H, then R53 is optionally substituted C3-C10 carbocyclyl;
• and if R53 is H and R55 is H, then R54 is optionally substituted C2-C9 heteroaryl,
• or a pharmaceutically acceptable salt thereof.